School of Life Science, Yunnan University, Kunming, Yunnan, China.
Gene. 2013 Jan 10;512(2):408-13. doi: 10.1016/j.gene.2012.09.085. Epub 2012 Oct 13.
p53 tumor suppressor gene Arg72Pro polymorphism has been associated with bladder cancer. However, results were inconsistent. We performed this meta-analysis to estimate the association between p53 Arg72Pro polymorphism and bladder cancer.
Electronic search of PubMed was conducted to select studies. Studies containing available genotype frequencies of Arg72Pro were chosen, and pooled odds ratio (OR) with 95% confidence interval (CI) was used to assess the association.
The final meta-analysis included 14 published studies with 2176 bladder cancer cases and 2798 controls. The results suggested that the variant genotype was associated with the bladder cancer risk (additive model: OR=1.72, 95% CI: 1.036-1.325, P=0.011; dominant model: OR=1.268, 95% CI: 1.003-1.602, P=0.047) in Asian subgroup. However, the association was not significant between this polymorphism and bladder cancer risk in Caucasian (additive model: OR=0.773, 95% CI: 0.564-1.059, P=0.109; dominant model: OR=0.685, 95% CI: 0.418-1.124, P=0.134).
This meta-analysis suggests that p53 Arg72Pro polymorphism is associated with increased risk of bladder cancer in Asians. To validate the association between this polymorphism and bladder cancer, further studies with larger participants worldwide are needed.
p53 肿瘤抑制基因 Arg72Pro 多态性与膀胱癌有关。然而,结果并不一致。我们进行了这项荟萃分析,以评估 p53 Arg72Pro 多态性与膀胱癌之间的关系。
通过电子搜索 PubMed 来选择研究。选择包含 Arg72Pro 可用基因型频率的研究,并使用合并优势比(OR)和 95%置信区间(CI)来评估相关性。
最终的荟萃分析包括 14 项已发表的研究,共有 2176 例膀胱癌病例和 2798 例对照。结果表明,变异基因型与膀胱癌风险相关(加性模型:OR=1.72,95%CI:1.036-1.325,P=0.011;显性模型:OR=1.268,95%CI:1.003-1.602,P=0.047)在亚洲亚组中。然而,在高加索人群中,这种多态性与膀胱癌风险之间的关联并不显著(加性模型:OR=0.773,95%CI:0.564-1.059,P=0.109;显性模型:OR=0.685,95%CI:0.418-1.124,P=0.134)。
这项荟萃分析表明,p53 Arg72Pro 多态性与亚洲人群膀胱癌风险增加有关。为了验证这种多态性与膀胱癌之间的关联,需要在全球范围内进行更多具有更大参与者的研究。